Health
Why Moderna Stock Climbed Today – Motley Fool
One analyst sees gains of nearly 40% ahead for the biotech’s shareholders.
What happened
Shares of Moderna (NASDAQ:MRNA) rose 6.8% on Friday, as analysts and investors grew more optimistic about the vaccine maker’s growth prospects.
So what
Piper Sandler analyst Edward Tenthoff repeated his overweight rating on Moderna’s stock and boosted his price forecast from $208 to $234 on Thursday. His new price target represents potential returns to shareholders of roughly 37% from Moderna’s current share price near $170.
Moderna’s stock price is up sharply in recent days. Image…
-
Business17 hours agoIs this the best ASX ETF to diversify your portfolio with?
-
General12 hours agoLiberals go back to basics after crawling to year’s end
-
Business17 hours ago3 of the best ASX ETFs to build significant wealth
-
General17 hours agoTrolls stole Dr Juliet Turner’s joy and in doing so took their own